# AstraZeneca > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/astrazeneca). ## Overview AstraZeneca is a UK-based biopharmaceutical company that discovers, develops, manufactures, and commercialises prescription medicines worldwide. Its portfolio spans oncology, rare disease, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology therapies, with operations in more than 100 countries. ## Products & services • Oncology medicines • Rare disease therapies • Cardiovascular, renal & metabolism medicines • Respiratory & immunology medicines • Vaccine and biologics collaborations • Clinical development and manufacturing capabilities - **Oncology** (40%) — Cancer medicines across multiple tumor types and treatment settings. - **BioPharmaceuticals** (35%) — Cardiovascular, renal & metabolism, and respiratory & immunology medicines. - **Rare Disease** (15%) — Specialty therapies for rare and often severe chronic conditions. - **Collaboration Revenue** (10%) — Milestones, royalties, and other income from partnered programs. - Oncology medicines - Rare disease therapies - Cardiovascular, renal & metabolism medicines - Respiratory & immunology medicines - Vaccine and biologics collaborations - Clinical development and manufacturing capabilities ## Customers AstraZeneca sells primarily to healthcare systems, hospitals, clinics, and pharmacies that dispense prescription medicines to patients. It also works through government and public-health buyers in certain programs, as well as collaboration partners that help develop, manufacture, or distribute selected products. Demand is driven by physician prescribing, reimbursement access, regulatory approval, and inclusion in treatment protocols. - **Hospitals and cancer centers** (primary) — Buy oncology medicines for use in specialist treatment pathways and infusion settings. - **Specialist physicians and clinics** (primary) — Prescribe respiratory, renal, cardiovascular, and rare disease therapies for chronic care. - **Payers and public health systems** (primary) — Influence access through reimbursement, formulary placement, and procurement decisions. - **Government and multilateral buyers** (secondary) — Purchase vaccines and public-health products through advance purchase or supply agreements. - **Biopharma collaboration partners** (secondary) — Share development, manufacturing, and commercialization economics on partnered assets. - Hospitals and oncology centers treating complex cancers - Physicians and specialty clinics prescribing chronic therapies - Public health agencies and governments for vaccine supply - Pharmacies and distributors that channel prescription medicines - Collaboration partners sharing development, manufacturing, or profits ## Geography AstraZeneca operates globally, with commercial activity in more than 100 countries and a base in Cambridge, UK. Its business is geographically diversified across North America, Europe, and Asia, with emerging markets also important to growth and product mix. Manufacturing, R&D, and supply-chain execution are internationally distributed, which makes the company sensitive to regulatory, currency, and cross-border supply risks. - Headquartered in Cambridge, United Kingdom - Commercial operations span more than 100 countries - Large exposure to North America, Europe, and Asia - Emerging markets contribute to product mix and access - Global manufacturing and supply chains support worldwide launches ## Strategy AstraZeneca’s strategy centers on advancing a deep pipeline, expanding launches in core therapeutic areas, and using business development to add new platforms and assets. The company also emphasizes manufacturing expansion, digital and systems investment, and a progressive dividend policy supported by an investment-grade balance sheet. - **Pipeline advancement and launch execution** (short-term) — Future growth depends on successful clinical readouts, approvals, and commercialization of new medicines. - **Manufacturing and supply expansion** (short-term) — Global demand and complex biologics require reliable capacity and compliant supply. - **Business development and portfolio building** (medium-term) — Acquisitions and collaborations add new technologies, modalities, and future revenue streams. - **Capital discipline and shareholder returns** (medium-term) — The company balances reinvestment with credit quality and a progressive dividend policy. - Advance late-stage pipeline and new medicine launches - Expand oncology and specialty-care franchises - Use business development to add platforms and assets - Increase manufacturing capacity and technology investment - Maintain investment-grade credit profile and dividend policy ## Risks AstraZeneca faces typical biopharma risks tied to clinical development, regulatory approval, patent protection, and the ability to launch and scale new medicines. It is also exposed to pricing and access pressure, manufacturing and supply-chain disruption, litigation, cybersecurity, and foreign exchange volatility because its products and operations are global and highly regulated. - **Pipeline and clinical development risk** [high] — Drug candidates may fail in trials, miss endpoints, or be delayed by regulators. - **Intellectual property and patent challenges** [high] — Loss of exclusivity or adverse IP rulings can accelerate generic or biosimilar competition. - **Pricing, affordability, and access pressure** [high] — Payers and governments can restrict reimbursement or negotiate lower prices. - **Manufacturing and supply-chain execution** [medium] — Biologics and global distribution require compliant, uninterrupted supply. - **Legal and regulatory compliance** [medium] — Product liability, antitrust, and anti-corruption issues can lead to fines or restrictions. - Pipeline failure or delay can reduce future product growth - Patent and IP disputes can shorten exclusivity periods - Pricing and reimbursement pressure can limit market access - Manufacturing or supply issues can disrupt medicine availability - Litigation, investigations, and compliance failures can create liabilities - FX volatility affects reported results and cash flows ## Accounting AstraZeneca’s reported results are affected by collaboration revenue, milestone income, and profit-sharing arrangements, which can make revenue mix and gross margin less linear than pure product sales. Investors should also watch acquisition accounting for business combinations, fair-value estimates for in-development assets, contingent consideration, contingent liabilities, and foreign-exchange hedge accounting. - **Collaboration revenue and milestone recognition** — Affects quarterly comparability and revenue mix - **Profit-sharing arrangements** — Influences gross margin and cost of sales - **Business combination valuation** — Affects goodwill, intangible assets, and future amortization - **Contingent liabilities and legal provisions** — Can materially affect expenses and balance sheet reserves - **Foreign exchange hedging** — Affects earnings timing and OCI - Collaboration revenue and milestones can create lumpy quarterly results - Profit-sharing deals affect gross margin and cost of sales presentation - Business combinations require fair-value estimates for acquired pipelines - Contingent consideration can change with regulatory outcomes - Legal provisions and contingent liabilities depend on case outcomes - FX hedging affects reported earnings and OCI timing --- *Last updated: 2026-08-11T04:04:51.002122+00:00*